EGF
An endogenous 53-amino-acid growth factor that binds EGFR to drive skin regeneration, wound re-epithelialization, and collagen production.
Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR / ErbB1) to stimulate proliferation, migration, and differentiation of epithelial and mesenchymal cells. It plays a fundamental role in wound healing, skin regeneration, and tissue repair by activating keratinocytes and fibroblasts through tyrosine kinase-mediated PI3K/Akt and MAPK/ERK signaling. Recombinant human EGF has been evaluated clinically for diabetic and chronic wound healing and is widely used in cosmetic formulations, though it holds no FDA approval in the United States.
Class
Endogenous 53-amino-acid growth factor polypeptide (EGFR ligand)
Routes
Topical, Subcutaneous, Microneedling
Category
Healing & Recovery
Researched benefits
What it's studied for
Wound healing and re-epithelialization
Topically applied recombinant EGF accelerates epithelialization and granulation tissue formation. A pilot clinical trial in diabetic foot ulcers reported a positive granulation response in 100% of patients and complete healing in over half by 8 weeks.
Skin regeneration
By activating keratinocyte and fibroblast proliferation through EGFR tyrosine kinase signaling, EGF supports renewal of epithelial tissue and is a common ingredient in regenerative skin formulations.
Collagen and hyaluronic acid stimulation
EGF signaling stimulates fibroblasts to produce collagen and hyaluronic acid, contributing to its cosmetic and tissue-repair rationale, though clinical benefit at cosmetic concentrations has not been independently validated.
Post-procedure recovery
EGF is used in the context of post-procedure skin recovery, leveraging its role in accelerating epithelial repair and granulation after skin injury or microneedling.
Chronic and diabetic wound bed preparation
Injectable EGF has been evaluated for wound bed preparation in diabetic and chronic wounds, where endogenous repair signaling is impaired.
Mechanism
How it works
EGF binds the EGF receptor (EGFR, also called ErbB1), a receptor tyrosine kinase on the surface of epithelial and mesenchymal cells. Ligand binding triggers receptor dimerization and autophosphorylation of intracellular tyrosine residues, creating docking sites for downstream signaling proteins.
Activated EGFR initiates two principal proliferative cascades: the RAS/MAPK/ERK pathway and the PI3K/Akt pathway. Together these drive cell proliferation, migration, survival, and differentiation, which underlie EGF's effects on tissue growth and repair.
In skin and wound contexts, this signaling promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization and granulation tissue formation, and stimulates production of collagen and hyaluronic acid. Because the same proliferative signaling that aids healing can also support tumor cell growth, EGFR activity is closely linked to cancer biology, which informs EGF's contraindication in active cancer contexts.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Clinical (diabetic foot ulcer study)
- Dose
- Recombinant human EGF (rh-EGF), concentration not standardized across sources
- Frequency
- Twice daily
- Timing
- Applied to the wound bed
- Duration
- Up to 8 weeks in the reported pilot trial
- Route
- Topical
In a 28-patient pilot study, twice-daily rh-EGF produced a positive granulation response in 100% of patients with complete healing in 56.5% at 8-week follow-up.
- The available sources do not provide standardized cosmetic or research dosing concentrations, reconstitution volumes, or a defined half-life for EGF.
- Cosmetic formulations incorporate EGF at concentrations where receptor activation and clinical benefit have not been independently validated.
- Reported administration routes include topical, subcutaneous, and microneedling; injectable EGF has been used specifically for diabetic and chronic wound bed preparation.
Evidence
Research & clinical studies (6)
The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results
In a pilot study of 28 diabetic foot ulcer patients, twice-daily rh-EGF produced a positive granulation response in 100% of patients, complete healing in 56.5% at 8 weeks, and wound closure rates of 43-85% across weeks 2-8 with good tolerability.
PMID 19432666Multi-omics profiling reveals epidermal growth factor as a potential biomarker and therapeutic target in lupus nephritis and ANCA-associated vasculitis with rapidly progressive glomerulonephritis
EGF is significantly downregulated in kidney tissue from patients with lupus nephritis and ANCA-associated vasculitis and correlates with impaired kidney function, suggesting it may serve as a biomarker and therapeutic target.
PMID 42213678Determinants of extraction efficiency in human amniotic membrane processing: biological, mechanical, and biochemical factors shaping growth factor yield
EGF extraction efficiency from human amniotic membrane depends on interdependent factors including tissue preservation, cryogenic processing, buffer composition, and protease inhibition, which can be optimized to enhance recovery of standardized high-potency extracts.
PMID 42207341Single-cell and spatial transcriptomic profiling reveals the expression characteristics of PTPRR in epithelial cells and its potential implications in pancreatic cancer metastasis
PTPRR is upregulated in pancreatic ductal adenocarcinoma epithelial cells and promotes migration and invasion via MAPK and RAS signaling, correlating with metastasis and poor outcomes.
PMID 42212130Germline MET-2-LIN-3-LET-23 signaling axis governs nanoplastic-induced transgenerational reproductive toxicity in Caenorhabditis elegans
Chronic polystyrene nanoparticle exposure triggers a signaling cascade involving the EGF ligand LIN-3 that is transmitted across generations to promote reproductive toxicity and cell death in C. elegans offspring.
PMID 42214197Associations between plasma BDNF, VEGF, and EGF and cognition in drug-naive schizophrenia with and without sleep disturbances
In drug-naive schizophrenia, EGF showed only a nominal exploratory association with sleep medication use while BDNF drove robust cognitive correlations, suggesting EGF plays a more limited role in cognitive outcomes.
PMID 42215707Safety
Side effects & considerations
Contraindications & cautions
- Active cancer or cancer history
- Pregnancy or nursing
EGF carries a moderate risk profile in research contexts. Because EGFR signaling drives cell proliferation, it is contraindicated in individuals with active cancer or a cancer history, and in those who are pregnant or nursing. Review contraindications and consult a qualified healthcare professional before use.
FAQ
EGF — common questions
What is EGF?
Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR) to stimulate cell proliferation, migration, and differentiation in epithelial and mesenchymal cells. It plays a fundamental role in wound healing, skin regeneration, and tissue repair by activating keratinocytes and fibroblasts through tyrosine kinase-mediated PI3K/Akt and MAPK/ERK signaling.
What is EGF primarily studied for?
Skin regeneration, wound healing, collagen stimulation, and post-procedure recovery. Injectable EGF has also been evaluated for wound bed preparation in diabetic and chronic wounds.
What does the research show about EGF?
Clinical trials of recombinant human EGF for wound healing, including a pilot trial in diabetic foot ulcers, have demonstrated improvements in wound closure and tissue regeneration. Overall the evidence is graded as emerging, based on six cited studies, several of which examine EGF as a biomarker or signaling component rather than as a therapeutic.
How is EGF administered?
Reported routes include topical application, subcutaneous injection, and microneedling. In the diabetic foot ulcer study, recombinant human EGF was applied topically twice daily to the wound bed.
Is EGF FDA approved?
No. Topically applied EGF has no FDA approval in the United States for wound healing or cosmetic use and is designated research-only. Recombinant EGF wound therapeutics are approved in some countries, such as Cuba and South Korea, for diabetic wound healing under prescription conditions.
What are the side effects and contraindications of EGF?
EGF has a moderate risk profile. Reported contraindications include active cancer or a cancer history and pregnancy or nursing, reflecting concern that proliferative EGFR signaling could support tumor growth. Consult a qualified healthcare professional before use.
Does EGF in cosmetic products work?
EGF is widely incorporated into cosmetic formulations, but at the concentrations used, receptor activation and clinical benefit have not been independently validated.
